Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
OwnerHerman H. Fudenberg, Harrell D. Whitten +1inventors
InventorsHerman H. Fudenberg, Harrell D. Whitten, Nemat Khansari
Life of this patent
Estimating the term…
Abstract
A method is provided for recognizing and diagnosing diseases or conditions associated with immune system dysfunction and loss of integration of brain function, particularly a subset of Alzheimer's disease, and for the in vitro testing to determine efficacy of possible therapeutic agents. The method involves measurement of immunological parameters on peripheral blood immunocytes.
Claims11
A method of diagnosing a degenerative disease of the central nervous system associated with the impairment of integrative brain function, comprising
- (a) providing a peripheral blood sample from a patient,
- (b) measuring the level of interactive T cells of said peripheral blood, and
- (c) determining whether the patient suffers from a degenerative disease of the central nervous system associated with the impairment of integrative brain function by comparing said level with a predetermined standard level indicative of the degenerative disease or with a predetermined standard level indicative of normality.
A method for the in vitro testing of the efficacy of a therapeutic agent in treating a degenerative disease or condition of the central nervous system associated with the impairment of integrative brain function comprising
- (a) taking a peripheral blood sample from an individual known to be suffering from a degenerative disease or condition of the central nervous system associated with the impairment of integrative brain function,
- (b) measuring the level of interactive T cells of said sample,
- (c) exposing said sample to the action of a therapeutic agent in a predetermined dosage for a predetermined period of time, and again
- (d) measuring said level of interactive T cells, whereby a change in said level toward a predetermined standard level indicative of normality, is suggestive of efficacy of the therapeutic agent.
A method of distinguishing Alzheimer's disease from another senile dementia, comprising
- (a) providing a peripheral blood sample from a patient,
- (b) measuring the level of interactive T cells of said peripheral blood, and
- (c) determining whether the patient suffers from Alzheimer's disease or another senile dementia by comparing said level with a predetermined standard level indicative of Alzheimer's disease and a predetermined standard level indicative of another senile dementia.
A method of diagnosing in a patient a disease characterized by a structural brain abnormality comprising
- (a) providing a peripheral blood sample from a patient,
- (b) measuring the level of interactive T cells of said peripheral blood, and
- (c) determining whether the patient suffers from a disease characterized by a structural brain abnormality by comparing said level with a predetermined standard level indicative of the disease or with a predetermined standard level indicative of normality.
A method of diagnosing in a patient a disease characterized by reduced levels of choline acetyltransferase or acetylcholine esterase comprising
- (a) providing a peripheral blood sample from a patient,
- (b) measuring the level of interactive T cells of said peripheral blood, and
- (c) determining whether the patient suffers from a disease characterized by reduced levels of choline acetyltransferase or acetylcholine esterase by comparing the level of interactive T cells with a predetermined standard level indicative of the disease or with a predetermined standard level indicative of normality.
A method of diagnosing in a patient a dementing disorder comprising
- (a) providing a peripheral blood sample from a patient,
- (b) measuring the level of interactive T cells of said peripheral blood, and
- (c) determining whether the patient suffers from a dementing disorder by comparing said level with a predetermined standard level indicative of the dementing disorder or with a predetermined standard level indicative of normality.
A method of in vitro testing a substance for potential nootropic action comprising
- (a) providing a sample of peripheral blood immunocytes from a patient,
- (b) contacting said immunocytes with a substance with potential nootropic action,
- (c) observing the effect of said substance on the ability of said immunocytes to form rosettes with human B lymphoid cells, the level of rosettes formed being an indication of the nootropic action of said substance.
A method of in vitro testing a substance for potential therapeutic use against a dementing disorder comprising
- (a) providing a sample of peripheral blood immunocytes from a patient,
- (b) contacting said immunocytes with a substance with potential nootropic action,
- (c) observing the effect of said substance on the ability of said immunocytes to form rosettes with human B lymphoid cells, the level of rosettes formed being an indication of the therapeutic efficacy of said substance.
Dependencies are inferred from the claim text.